Welcome, Introduction, and Baseline Assessment - 5 minutes
CCO will set the stage by welcoming attendees, reviewing housekeeping notes, and explaining the webinar format as well as asking demographics and presurvey questions.
Presentation 1: Review of Recent Approvals and Expanded Indications in MM - 20 minutes
- Frontline treatment algorithms and summary of new approvals
- Relapsed/refractory (R/R) treatment algorithms and summary of new approvals
- Adapting therapy to individualize each patient’s care
- Incorporating disease characteristics and patient preferences, shared decision-making considerations
- Considerations for elderly patients
- Rationale for using new classes of drugs in each line of therapy
- Administration and dosing considerations (IV vs SQ, all oral regimens, etc)
Presentation 2: Supportive Care Challenges in Patients With MM and How to Overcome Them - 20 minutes
- Management of disease-related and treatment-related AEs
- Available data and insights on managing MM bone disease
- Management of AEs associated with agents from new classes
- Belantamab mafodotin
- Immunotherapy approaches
- Administration considerations for monoclonal antibodies
- Patient adherence issues, comorbidities, frailties, psychosocial support
Future Directions for Patients With MM: Ongoing Clinical Trial Spotlight - 15 minutes
- Novel combination therapies and optimal sequencing
- Novel targeted agents
- Venetoclax- summary slide
- Melflufen- summary slide
- BCMA-targeted therapies-
- Antibody–drug conjugates (MEDI2228, CC-99712)
- BiTEs and bispecific monoclonal antibodies (AMG 420, AMG 701, REGN5458, CC-93269, JNJ-64007957, PF-06863135)
- CAR T-cell therapy (idecabtagene vicleucel, bb21217, JCARH125, JNJ-68284528 (LCAR-B38M), P-BCMA-101, ALLO-715, etc)
Date / Time
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Nell Hodgson Woodruff School of Nursing
The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with multiple myeloma.
This program is intended for oncology nurses and other healthcare providers who care for patients with multiple myeloma.
- Provide patient-focused education on the available clinical data and new therapeutic options for the individualized treatment of MM
- Discuss with patients the available data and rationale for using monoclonal antibodies as well as new-generation immunomodulatory agents and proteasome inhibitors for individual patients with MM
- Evaluate individualized treatment strategies for elderly patients through consideration of the available clinical data as well as risk assessment, comorbidities, and patient preferences
- Develop a proactive management plan for adverse events associated with recently approved agents and novel combinations used to treat MM
- Manage the physical, emotional, and social challenges experienced by patients diagnosed with MM through all stages of their disease
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Nursing Continuing Education
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.